- Home
- NGNE vs LFCR Comparison
NGNE vs LFCR Comparison
Compare NGNE & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- LFCR
- Stock Information
- Founded
- NGNE 2003
- LFCR 1986
- Country
- NGNE United States
- LFCR United States
- Employees
- NGNE N/A
- LFCR N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- LFCR Biotechnology: Pharmaceutical Preparations
- Sector
- NGNE Health Care
- LFCR Health Care
- Exchange
- NGNE Nasdaq
- LFCR Nasdaq
- Market Cap
- NGNE 325.3M
- LFCR 308.8M
- IPO Year
- NGNE N/A
- LFCR N/A
- Fundamental
- Price
- NGNE $18.48
- LFCR $7.61
- Analyst Decision
- NGNE Strong Buy
- LFCR Buy
- Analyst Count
- NGNE 7
- LFCR 4
- Target Price
- NGNE $41.86
- LFCR $8.00
- AVG Volume (30 Days)
- NGNE 110.1K
- LFCR 108.3K
- Earning Date
- NGNE 08-11-2025
- LFCR 08-07-2025
- Dividend Yield
- NGNE N/A
- LFCR N/A
- EPS Growth
- NGNE N/A
- LFCR N/A
- EPS
- NGNE N/A
- LFCR N/A
- Revenue
- NGNE N/A
- LFCR $128,867,000.00
- Revenue This Year
- NGNE N/A
- LFCR $4.78
- Revenue Next Year
- NGNE N/A
- LFCR $12.02
- P/E Ratio
- NGNE N/A
- LFCR N/A
- Revenue Growth
- NGNE N/A
- LFCR 0.47
- 52 Week Low
- NGNE $6.88
- LFCR $3.68
- 52 Week High
- NGNE $74.49
- LFCR $8.85
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- LFCR 53.94
- Support Level
- NGNE $19.59
- LFCR $7.33
- Resistance Level
- NGNE $20.46
- LFCR $7.73
- Average True Range (ATR)
- NGNE 1.23
- LFCR 0.30
- MACD
- NGNE -0.20
- LFCR 0.03
- Stochastic Oscillator
- NGNE 13.37
- LFCR 65.33
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.